Aurobindo Irbesartan Class Action Settlement -- $2 Million for Contaminated Blood Pressure Drug

vs. Aurobindo Pharma

Payout Range

Varies

Deadline

6/2/2026

Time Left

47 days

Sign up to file this claim →

About this settlement

Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc., and Aurolife Pharma LLC have agreed to a $2,000,000 class action settlement to resolve economic loss claims that the company manufactured and sold irbesartan blood pressure drugs allegedly contaminated with NDEA -- a probable human carcinogen.

Who is eligible

No specific eligibility requirements listed. Review the official settlement terms for complete criteria.

Who is in the settlement class

Individuals in the United States who, from January 1, 2016 to the present, paid any amount of money for retail purchases of irbesartan finished drug formulations manufactured using Aurobindo irbesartan API.

How to claim

This settlement has the following claim path.

Pro rata cash payment

Variable (pro rata)

Payments will be made pro rata, meaning the more you spent, the larger your share.

✓ No documentation required — self-attestation only

How to file

This settlement accepts online and mail claim submissions. Pick whichever is easier.

File online
https://www.sartanmedicationsettlement.com
Mail to
Sartan Medication Settlement Administrator
P.O. Box 3376
Baton Rouge, LA 70821

Official settlement information

https://openclassactions.com/settlements/aurobindo-irbesartan-contaminated-blood-pressure-drug-class-action-settlement.php

ClaimHawk is an independent service. Review the official settlement site for legally binding terms.

How ClaimHawk helps you file

  • ✓ Pre-fills your claim form from your encrypted profile
  • ✓ Scans your ID and receipts automatically
  • ✓ Generates the filled claim form as a PDF
  • ✓ Texts you a reminder the week of the deadline
Sign up free →